Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Series B round brings in $38.5mm for Otonomy

31 Aug 2010

Executive Summary

Three months after closing its $10mm Series A venture round, Otonomy Inc. (therapeutics for ear disorders) has raised $38.5mm through its Series B. Novo Ventures and RiverVest Venture Partners co-led the financing and were joined by fellow new backers Domain Associates and TPG Biotech (all contribute one board member) and current shareholder Avalon Ventures. Otonomy will use the funds to continue developing Phase Ib OTO104 for Meniere's disease and preclinical OTO203 for otitis media.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By